NCT04524637 The Utility of Thromboelastography in Traumatic Brain Injury
| NCT ID | NCT04524637 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 6th People's Hospital |
| Condition | Traumatic Brain Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-09-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2018-09-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hemocoagulation disorder is recognized to have crucial effects on hemorrhagic or ischemic diseases. Coagulation-related damages secondary to traumatic brain injury are common and severe secondary insults of head trauma and often leads to a poor prognosis. In this study, we sought to assess if posttraumatic hemocoagulation disorders determined using thromboelastography are associated with coagulation-related damages secondary to traumatic brain injury, and evaluate their influence on outcome among patients with head trauma. Based on above results, prediction models or risk scoring systems will be further developed and validated to predict coagulation-related damages secondary to traumatic brain injury.
Eligibility Criteria
Inclusion Criteria: * Patients who are delivered to hospital within 24 hours after head trauma * Patients whose abbreviated injury score (AIS) for other body regions is 3 or less are considered to be isolated traumatic brain injury Exclusion Criteria: * Patients with existing prior neurological disease * Patients with known coagulation disorders * Patients on anticoagulants and medications known to affect coagulation function within 30 days before trauma * Patients receiving blood components prior to blood draw * Patients who deteriorate and die before determining whether coagulation- related damage exists
Contact & Investigator
Hao Chen, M.D., Ph.D.
STUDY DIRECTOR
Shanghai 6th People's Hospital
Frequently Asked Questions
Who can join the NCT04524637 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04524637 currently recruiting?
Yes, NCT04524637 is actively recruiting participants. Contact the research team at chenhao_316@aliyun.com for enrollment information.
Where is the NCT04524637 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04524637 clinical trial?
NCT04524637 is sponsored by Shanghai 6th People's Hospital. The principal investigator is Hao Chen, M.D., Ph.D. at Shanghai 6th People's Hospital. The trial plans to enroll 500 participants.